{"pmid":32311843,"title":"Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.","text":["Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.","In March 2020, the global healthcare system is overwhelmed by patients infected with SARS-CoV-2, which is the cause of the coronavirus pandemic (Covid-2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived.","Int J Lab Hematol","Beun, Robert","Kusadasi, Nuray","Sikma, Maaike","Westerink, Jan","Huisman, Albert","32311843"],"abstract":["In March 2020, the global healthcare system is overwhelmed by patients infected with SARS-CoV-2, which is the cause of the coronavirus pandemic (Covid-2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived."],"journal":"Int J Lab Hematol","authors":["Beun, Robert","Kusadasi, Nuray","Sikma, Maaike","Westerink, Jan","Huisman, Albert"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311843","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ijlh.13230","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1664632501441658881,"score":8.518259,"similar":[{"pmid":32267998,"title":"Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","text":["Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10).","J Thromb Haemost","Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D","32267998"],"abstract":["A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10)."],"journal":"J Thromb Haemost","authors":["Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267998","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jth.14828","keywords":["acute respiratory distress syndrome (ards)","covid-19","case report","fibrinolysis","tissue plasminogen activator (tpa)"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664637636082401280,"score":193.91965},{"pmid":32302462,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure.","J Thromb Haemost","Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E","32302462"],"abstract":["We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure."],"journal":"J Thromb Haemost","authors":["Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302462","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14860","keywords":["acute respiratory distress syndrome (ards)","anticoagulation","covid-19","disseminated intravascular coagulation","international society on thrombosis and haemostasis (isth)"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["ISTH"],"e_drugs":["Heparin","Heparin, Low-Molecular-Weight"],"_version_":1664635401358278656,"score":162.96667},{"pmid":32302445,"title":"Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","text":["Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2).","J Thromb Haemost","Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa","32302445"],"abstract":["We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2)."],"journal":"J Thromb Haemost","authors":["Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302445","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14852","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664635401350938627,"score":153.16231},{"pmid":32304577,"title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","text":["Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.","Br J Haematol","Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos","32304577"],"abstract":["Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present."],"journal":"Br J Haematol","authors":["Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304577","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16727","keywords":["sars-cov-2","anticoagulant","prophylaxis","thromboembolism","thrombosis"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["thromboprophylaxis"],"_version_":1664632934588481537,"score":149.60226},{"pmid":32294295,"title":"Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","text":["Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6).","J Thromb Haemost","Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara","32294295"],"abstract":["Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6)."],"journal":"J Thromb Haemost","authors":["Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294295","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14844","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664636192669302786,"score":146.89029}]}